These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24211838)

  • 1. Loss of CDH1 up-regulates epidermal growth factor receptor via phosphorylation of YBX1 in non-small cell lung cancer cells.
    Liu X; Su L; Liu X
    FEBS Lett; 2013 Dec; 587(24):3995-4000. PubMed ID: 24211838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
    Dobashi Y; Suzuki S; Kimura M; Matsubara H; Tsubochi H; Imoto I; Ooi A
    Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
    Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
    Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
    Song L; Morris M; Bagui T; Lee FY; Jove R; Haura EB
    Cancer Res; 2006 Jun; 66(11):5542-8. PubMed ID: 16740687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
    Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
    Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells.
    Akca H; Tani M; Hishida T; Matsumoto S; Yokota J
    Lung Cancer; 2006 Oct; 54(1):25-33. PubMed ID: 16872715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9.
    Dong QZ; Wang Y; Tang ZP; Fu L; Li QC; Wang ED; Wang EH
    Am J Pathol; 2013 Mar; 182(3):954-64. PubMed ID: 23306155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal activation of the EGFR signaling pathway mediates the downregulation of miR‑145 through the ERK1/2 in non-small cell lung cancer.
    Guo YH; Zhang C; Shi J; Xu MH; Liu F; Yuan HH; Wang JY; Jiang B; Gao FH
    Oncol Rep; 2014 Apr; 31(4):1940-6. PubMed ID: 24535036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
    Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
    Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
    Sordella R; Bell DW; Haber DA; Settleman J
    Science; 2004 Aug; 305(5687):1163-7. PubMed ID: 15284455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
    Haura EB; Zheng Z; Song L; Cantor A; Bepler G
    Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma.
    Liang C; Ma Y; Yong L; Yang C; Wang P; Liu X; Zhu B; Zhou H; Liu X; Liu Z
    Cancer Sci; 2019 Jan; 110(1):166-179. PubMed ID: 30426615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway.
    Cui W; Zhang S; Shan C; Zhou L; Zhou Z
    FEBS J; 2013 Aug; 280(16):3962-74. PubMed ID: 23786162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.
    Chou YT; Lin HH; Lien YC; Wang YH; Hong CF; Kao YR; Lin SC; Chang YC; Lin SY; Chen SJ; Chen HC; Yeh SD; Wu CW
    Cancer Res; 2010 Nov; 70(21):8822-31. PubMed ID: 20978205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.
    Loprevite M; Tiseo M; Chiaramondia M; Capelletti M; Bozzetti C; Bortesi B; Naldi N; Nizzoli R; Dadati P; Kunkl A; Zennaro D; Lagrasta C; Campanini N; Spiritelli E; Camisa R; Grossi F; Rindi G; Franciosi V; Ardizzoni A
    Clin Cancer Res; 2007 Nov; 13(21):6518-26. PubMed ID: 17975165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
    Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CMTM7 knockdown increases tumorigenicity of human non-small cell lung cancer cells and EGFR-AKT signaling by reducing Rab5 activation.
    Liu B; Su Y; Li T; Yuan W; Mo X; Li H; He Q; Ma D; Han W
    Oncotarget; 2015 Dec; 6(38):41092-107. PubMed ID: 26528697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer.
    Sonobe M; Nakagawa M; Takenaka K; Katakura H; Adachi M; Yanagihara K; Otake Y; Wada H; Tanaka F
    J Surg Oncol; 2007 Jan; 95(1):63-9. PubMed ID: 17192868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
    Kobayashi S; Shimamura T; Monti S; Steidl U; Hetherington CJ; Lowell AM; Golub T; Meyerson M; Tenen DG; Shapiro GI; Halmos B
    Cancer Res; 2006 Dec; 66(23):11389-98. PubMed ID: 17145885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
    Sato M; Vaughan MB; Girard L; Peyton M; Lee W; Shames DS; Ramirez RD; Sunaga N; Gazdar AF; Shay JW; Minna JD
    Cancer Res; 2006 Feb; 66(4):2116-28. PubMed ID: 16489012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.